Biopharma manufacturers see troubling parallels between the drug valuation work being done by the independently-operated Institute for Clinical and Economic Review (ICER) in the US and the UK’s National Institute for Health and Care Excellence (NICE), the price-approval body for National Health Service (NHS) drugs.
Companies are particularly concerned about ICER’s reliance on cost effectiveness analyses based on quality-adjusted life years (QALYs), which are also...







